Opioid Antagonist Nalmefene Shows Comparable Effectiveness to Naloxone
A Purdue Pharma study explored nalmefene and naloxone for the reversal of respiratory depression induced by fentanyl in a clinical opioid-induced respiratory depression model.
Tag: Narcan naloxone
All
Latest
Opioid Antagonist Nalmefene Shows Comparable Effectiveness to Naloxone
A Purdue Pharma study explored nalmefene and naloxone for the reversal of respiratory depression induced by fentanyl in a clinical opioid-induced respiratory depression model.
Read More
Implantable Device Senses Overdose, Automatically Delivers Naloxone
Implanted under the skin, the Naloximeter senses dropping oxygen and sends a warning notification to a mobile app. If the user doesn’t engage with the warning message within 30 seconds, the device releases stored naloxone.
Read More
Could Naloxone Improve Survival Rates in Cardiac Arrest Patients?
Surprisingly, naloxone was associated with improved clinical outcomes in both drug-related cardiac arrests and non-drug-related cardiac arrests.
Read More
Implant Detects Opioid Overdose and Automatically Administers Naloxone
The implantable device, tested in animal models, continuously monitors vital signs and automatically administers naloxone during opioid overdose.
Read More
A New Compound Could Make Narcan Even More Effective
Adding a newly identified compound makes naloxone more potent and longer lasting, a mouse study shows.
Read More
NIH’s Ambitious Plan to Curb Opioid Deaths Falls Short
A data-driven intervention engaging communities to deploy evidence-based practices did not significantly reduce opioid-related overdose deaths.
Read More
FDA Approves Amneal’s OTC Naloxone Nasal Spray
The nasal spray, available at pharmacies without a prescription, is designed to counteract opioid overdoses.
Read More
Opvee Opioid Rescue Spray Non-inferior to Intranasal Naloxone, Study Finds
A head-to-head pharmacodynamic study examined the ability of both intranasal nalmefene (Opvee) and intranasal naloxone to reverse opioid-induced respiratory depression.
Read More
Five Pharma Approvals from 2023
In some of the most notable pharmaceutical approvals from 2023, drugs for RSV, CF, COVID-19, sickle cell disease, and opioid overdose received an FDA stamp in 2023.
Read More
FDA Approves Second OTC Naloxone Nasal Spray
The US Food and Drug Administration approved a 3-milligram naloxone hydrochloride nasal spray for over-the-counter, nonprescription use for the emergency treatment of known or suspected opioid overdose.
Read MoreFDA Approves Narcan Nasal Spray for OTC Use
The FDA approved Narcan 4 mg naloxone hydrochloride nasal spray for over-the-counter, nonprescription use. The approval is the first for a naloxone product without a prescription.
Read MoreFDA Approves Amphastar’s Naloxone Nasal Spray
The FDA approved Amphastar Pharma’s naloxone hydrochloride nasal spray (4mg) for the emergency treatment of known or suspected opioid overdose.
Read More
NIH Harm Reduction Research Network Targets Opioid Overdose Fatalities
Harm reduction is an evidence-based, often life-saving approach that directly engages people who use drugs to prevent overdose, disease transmission and other harms.
Read More
Teva Generic Narcan Now Available to Treat Opioid Overdoses
Teva says its generic version of the nasal spray Narcan is the first to arrive on the market.
Read More
Kaleo to Pay $12.7M Over False Claim Allegations for Naloxone
Kaléo will pay the United States $12.7 million to resolve allegations that Kaléo caused the submission of false claims for the drug Evzio, an injectable form of naloxone hydrochloride for opioid overdose.
Read More
Opioid Overdose Deaths Increased 38% in Black Americans
A new NIH study found that non-Hispanic Black individuals in four US states experienced a 38% increase in the rate of opioid overdose deaths from 2018 to 2019, while the rates for other race and ethnicity groups held steady or decreased.
Read More
Higher Dosage of Naloxone Approved for Opioid Overdose
The FDA approved an 8mg dose naloxone hydrochloride nasal spray to treat opioid overdose, an increase from the previous 2 mg and 4 mg approved products.
Read More
Evzio Naloxone Auto-injector and Generic Discontinued
Kaleo Inc has discontinued its naloxone hydrochloride injection product Evzio and its authorized generic, according to industry reports.
Read MoreFDA Continues to Support Increased Access to Naloxone
Access to naloxone remains limited but the FDA continues to support efforts to expand access in order to get the drug to those at risk of opioid overdose.
Read More
Naloxone Access Law in Pennsylvania Falls Short
A new study from researchers at the University of Illinois at Chicago finds that only one-third of pharmacies in Philadelphia carry naloxone nasal spray, a medication used to rapidly counter the effects of opioid overdose.
Read More
Generic Evzio Naloxone Auto-Injection Available
Kaleo will offer an Evzio generic (naloxone HCl injection) at a list price of $178 per carton (two auto-injectors per carton).
Read More
Kaleo Criticized for Raising Price of Naloxone 500%
Kaleo, the company that makes a naloxone auto-injector called Evzio, is coming under fire for raising the price of a two-pack from $690 to $4500 since 2014.
Read More
FDA Seeks Mobile App to Combat Opioid Overdose
The FDA wants the proposed app to connect opioid users experiencing an overdose with nearby carriers of the prescription drug naloxone (the antidote for an opioid overdose).
Read More
ICUs Strained by Increased Volume, Near Doubling of Opioid-related Deaths
ICU admissions related to opioid overdoses are steadily increasing, and opioid overdose-related ICU deaths have nearly doubled since 2009.
Read More